Bank of New York Mellon Corp Reduces Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Bank of New York Mellon Corp reduced its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 6.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 225,017 shares of the company’s stock after selling 15,809 shares during the period. Bank of New York Mellon Corp’s holdings in Caribou Biosciences were worth $358,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PFM Health Sciences LP grew its holdings in Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares during the period. Geode Capital Management LLC grew its stake in shares of Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares in the last quarter. FMR LLC lifted its position in shares of Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after purchasing an additional 109,606 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Caribou Biosciences by 19.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after acquiring an additional 118,325 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Caribou Biosciences by 45.9% in the third quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock valued at $466,000 after purchasing an additional 74,799 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Down 5.0 %

NASDAQ CRBU opened at $0.94 on Friday. The company has a market capitalization of $87.34 million, a PE ratio of -0.57 and a beta of 2.34. The stock has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $1.71. Caribou Biosciences, Inc. has a 12 month low of $0.88 and a 12 month high of $5.15.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, sell-side analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRBU has been the subject of several research reports. Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences currently has an average rating of “Buy” and an average price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.